- Details
- Drs Maha Hussain and Fred Saad join Dr Alicia Morgans in a conversation on PARP combination therapy in prostate cancer and the status of its use in clinical practice. In this context, the group discusses the PROpel and the MAGNITUDE studies data and how the data can be used in clinical practice. Biographies: Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the Divisi...
|
- Details
- Oliver Sartor is joined by Alicia Morgans to discuss her presentation at the GU ASCO 2022 Annual Meeting on the largest digital survey conducted in patients with prostate cancer, the initial results of an international survey of patients with prostate cancer. The goal of this survey was to map patient experiences, expectations, and attitudes, and to identify challenges and unmet needs in diagnosis...
|
- Details
- Andrey Soares joins Phillip Koo at the 13th International Uro-Oncology Conference in Sao Paulo, Brazil in a conversation on challenges and opportunities in the management of patients with high risk localized disease in Latin America as well as the ARASENS data in the metastatic castration sensitive prostate cancer setting. Dr, Soares elaborates on the work that still needs to be done in Brazil to...
|
- Details
- Nicholas James joins Phillip Koo at the 13th International Uro-Oncology Conference in Brazil to discuss his presentation on the lessons learned from the STAMPEDE trial which shed insight into how we can improve the outcomes for men with metastatic prostate cancer. Professor James' lecture focuses on how Latin American countries can implement these lessons in conducting and setting up clinical tria...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the JAMA Oncology article titled "Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone." The authors of this study aimed to investigate the differences in outcomes with first-line abiraterone therapy between African American and non-Hispanic White men with mCRPC in...
|
- Details
- Alicia Morgans is joined by Frank Schumacher to discuss the study results assessing the association of functional outcomes by decision-making approaches in men with metastatic prostate cancer. Dr. Schumacher and colleagues assessed the association of shared decision-making vs. physician- or patient-directed decisions and measurement of patient quality of life, including patient-reported functional...
|
- Details
- Charles Ryan is joined by Neil Fleshner to discuss the multi-center, open-label, phase III SPLASH study evaluating the efficacy of 177Lu-PNT2002, a PSMA-based radioligand, for men with progressive metastatic castration-resistant prostate cancer (mCRPC) after androgen receptor axis-targeted (ARAT) therapy which is underway and accruing in many sites around the world. Biographies: Neil Fleshner, MD,...
|
- Details
- Phillip Koo is joined by Joseph Osborne to provide a nuclear radiologist's perspective on the equity in prostate cancer clinical trials. Dr. Osborne focuses his talk on three different aspects of clinical trial equity for prostate cancer: Progress, Evolution, and Goals. He also details the Rad Health Equity Lab, created at Weill Cornell to improve access to radiology and bring awareness to health...
|
- Details
- Alicia Morgans and Silke Gillessen discuss the upcoming Advanced Prostate Cancer Consensus Conference scheduled as a hybrid meeting taking place on April 28 - 30, 2022 in Lugano, Switzerland. Clinical management of prostate cancer will be discussed including locally advanced high-risk prostate cancer, biochemical recurrence in prostate cancer, and metastatic hormone-sensitive patient treatments, w...
|
- Details
- In this discussion between Kara Maxwell and Alicia Morgans, Dr Maxwell highlights the role of TP53 in cancer and understanding the Li-Fraumeni syndrome. Inherited germline TP53 pathogenic and likely pathogenic variants (gTP53) cause autosomal dominant multicancer predisposition including Li-Fraumeni syndrome and the work that Drs. Morgans and Maxwell discuss here sought to determine whether gTP53...
|
